
Regeneron's Livsayis (cemdisiran) gains FDA approval for adults with antibody-positive generalized myasthenia gravis, dosed four times a year.
Oriana Schwindt
Associate Editor
Oriana Schwindt worked as a reporter, writer, and researcher at several national publications (among them, BusinessWeek and Entertainment Weekly) before joining the Pharm Exec team as Associate Editor. She holds a BS in Journalism from the Medill School of Journalism at Northwestern University.






